EUSA

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

Retrieved on: 
Friday, December 3, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, PARP, Overalls, Company, NMPA, Siltuximab, Bristol Myers Squibb, Medication package insert, Effectiveness, Idiopathic multicentric Castleman disease, EU, Neoplasm, Diarrhea, Jazz Pharmaceuticals, Marketing, Global health, Tislelizumab, MCD, HIV, Private Securities Litigation Reform Act, Approved, Product, Anaphylaxis, Lymphoma, General manager, Research, Arthralgia, Itch, Respiratory tract, Review, Infection, Rash, EUSA, Therapy, Goal, U.S. Securities and Exchange Commission, Intellectual property, BTK, Twitter, Adult, NASDAQ, Lymph, FDA, Multimedia, HHV-8, Patient, Tissue, National Medical Products Administration, Safety, Technology, Novartis, IL-6, Degenerative disease, Thoracic duct, COVID-19, EMA, Union, Disease, Vaccine, Pharmaceutical industry, SYLVANT® (siltuximab for injection), EUSA Pharma, BeiGene, SYLVANT® (SILTUXIMAB FOR INJECTION), EUSA PHARMA, BEIGENE

Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world.

Key Points: 
  • Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world.
  • This approval is our second product in our collaboration with EUSA, highlighting the combined expertise of our companies as we work together on behalf of patients.
  • Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease.
  • We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma, and Bio-Thera.

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

Retrieved on: 
Friday, December 3, 2021
Science, Biotechnology, Research, Pharmaceutical, Physical Therapy, Health, Infectious Diseases, Clinical Trials, PARP, Overalls, Company, NMPA, Siltuximab, Bristol Myers Squibb, Medication package insert, Effectiveness, Idiopathic multicentric Castleman disease, EU, Neoplasm, Diarrhea, Jazz Pharmaceuticals, Marketing, Global health, Tislelizumab, MCD, HIV, Private Securities Litigation Reform Act, Approved, Product, Anaphylaxis, Lymphoma, General manager, Research, Arthralgia, Itch, Respiratory tract, Review, Infection, Rash, EUSA, Therapy, Goal, U.S. Securities and Exchange Commission, Intellectual property, BTK, Twitter, Adult, NASDAQ, Lymph, FDA, HHV-8, Patient, Tissue, National Medical Products Administration, Safety, Technology, Novartis, IL-6, Degenerative disease, Thoracic duct, COVID-19, EMA, Union, Disease, Vaccine, Pharmaceutical industry

Todays approval provides a new treatment for patients in China with this rare systemic disorder, commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene.

Key Points: 
  • Todays approval provides a new treatment for patients in China with this rare systemic disorder, commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene.
  • This approval is our second product in our collaboration with EUSA, highlighting the combined expertise of our companies as we work together on behalf of patients.
  • Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease.
  • We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma, and Bio-Thera.

ReForm Biologics Names Industry Veteran Jeff Hackman as President and Chief Executive Officer

Retrieved on: 
Wednesday, September 8, 2021
Biotechnology, Health, Science, Pharmaceutical, Research

ReForm Biologics , Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Jeffrey S. Hackman as President and Chief Executive Officer (CEO).

Key Points: 
  • ReForm Biologics , Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Jeffrey S. Hackman as President and Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20210908005435/en/
    Jeff Hackman joins ReForm Biologics as we advance our programs to address the needs of vulnerable patients who are less able to tolerate intravenous infusions, said Jim Sherblom, ReForms Executive Chairman.
  • Im honored to lead ReForm in this exciting role and spearhead our effort to develop and ultimately commercialize this transformative technology platform, said Jeff Hackman.
  • Prior to joining ReForm, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases.

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China

Retrieved on: 
Monday, January 25, 2021
AIDS, Health, Clinical trials, Research, Pharmaceutical, Science, Life sciences, Biotechnology, Health care, Siltuximab, BeiGene, National Medical Products Administration, Jazz Pharmaceuticals, Biopharmaceutical, Biologics license application, National Music Publishers Association, EUSA, BLA, Siltuximab, EUSA Pharma, BeiGene

EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review.

Key Points: 
  • EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review.
  • Siltuximab is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.
  • Lee Morley, Chief Executive Officer of EUSA Pharma, said, The BLA acceptance of siltuximab for review in China represents another exciting step in delivering therapies to patients in need worldwide.
  • We will continue in our close collaboration with BeiGene and the NMPA to potentially bring siltuximab to iMCD patients in China.

Ergomed Announces Provision of Clinical Research Services for COVID-19 Clinical Study

Retrieved on: 
Wednesday, March 18, 2020
Jazz Pharmaceuticals, Clinical research, EUSA, Pharma, Health

The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).

Key Points: 
  • The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).
  • Ergomed is providing clinical research services for the study and has been integrally involved in the design and implementation of the study from a clinical and operational perspective.
  • Ergomed is proud to be making a contribution to this effort by bringing our proven capabilities and expertise to bear on this important study.
  • Ergomed plc (LSE: ERGO), a company focused on providing specialized services to the pharmaceutical industry, is providing clinical research services for the study.

EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China

Retrieved on: 
Monday, January 13, 2020
Monoclonal antibodies, Financial markets, Dinutuximab, Siltuximab, EUSA, Hong Kong Exchanges and Clearing, Finance, Economy of Hong Kong

and BEIJING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- EUSA Pharma (EUSA) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an exclusive development and commercialization agreement for the orphan biologic products SYLVANT (siltuximab) and QARZIBA (dinutuximab beta) in Greater China.

Key Points: 
  • and BEIJING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- EUSA Pharma (EUSA) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an exclusive development and commercialization agreement for the orphan biologic products SYLVANT (siltuximab) and QARZIBA (dinutuximab beta) in Greater China.
  • Under the terms of the agreement, EUSA has granted BeiGene exclusive rights to SYLVANT in Greater China and to QARZIBAin mainland China.
  • Under the agreement, BeiGene will fund and undertake all clinical development and regulatory submissions in the territories, and will launch and commercialize both products once approved.
  • BeiGene brings to our collaboration exceptional development and commercialization capabilities in China and a clear focus on delivering innovative, targeted oncology medicines.

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA® in Spain

Retrieved on: 
Tuesday, April 23, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Chemical compounds, Organic compounds, Isoxazoles, Quinolines, Tivozanib, Ureas, Jazz Pharmaceuticals, EUSA, Aveos Fleet Performance

AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma.

Key Points: 
  • AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma.
  • The milestone payment relates to the reimbursement approval and commercial launch in Spain of FOTIVDA (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC).
  • Commercial launch in Spain is the third of five EU5 country launches to trigger a $2 million payment under the terms of AVEOs license agreement with EUSA Pharma.
  • EUSA Pharma is the licensee for tivozanib in Europe, North and South Africa, Latin America and Australasia.

EUSA Pharma Completes Acquisition of Global Rights to SYLVANT® (Siltuximab) and Presents Company Update at 37th J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 9, 2019
Jazz Pharmaceuticals, EUSA, Siltuximab, Biotechnology

EUSA intends to commercialize SYLVANT through its worldwide commercial platform, which it plans to expand further into a number of new markets.

Key Points: 
  • EUSA intends to commercialize SYLVANT through its worldwide commercial platform, which it plans to expand further into a number of new markets.
  • Its team of 30 specialist oncology representatives and medical science liaisons are currently undergoing training and EUSA plans to re-launch SYLVANT across the United States during January.
  • EUSA is currently planning to invest in developing SYLVANT in additional indications where IL-6 blockade may be indicated.
  • Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease.

EUSA Pharma Appoints Jeffrey S. Hackman as President US Operations

Retrieved on: 
Wednesday, December 5, 2018
Jazz Pharmaceuticals, EUSA

- EUSA to Open New US Headquarters in Boston, MA -

Key Points: 
  • - EUSA to Open New US Headquarters in Boston, MA -
    EUSA Pharma (EUSA), a global biopharmaceutical company with a focus on oncology and rare disease, today announced the appointment of Jeffrey S. Hackman as President of its United States' operations.
  • Mr Hackman will lead a major expansion of the company's US organization, as EUSA completes its transatlantic commercial infrastructure.
  • Jeffrey S. Hackman brings to EUSA 30 years' commercial pharmaceutical experience, including extensive expertise gained in the oncology field.
  • Jeffrey S. Hackman, EUSA Pharma's President, United States, said, "I am thrilled to join EUSA at this exciting time for the company.